Quick summary
Thymalin is a thymic peptide bioregulator developed by Vladimir Khavinson, used in Russian clinical medicine since 1982 for immune system restoration. Long-term studies suggest significant mortality reduction in elderly patients receiving thymalin combined with epithalon.
Overview
Thymalin is a thymic peptide bioregulator developed by Vladimir Khavinson (the same researcher behind Epithalon) from bovine thymus extracts. It has been used in Russian clinical medicine since 1982 for immune system restoration, particularly in immunocompromised patients, the elderly, and post-surgical recovery. Khavinson's long-term studies suggest significant mortality reduction in elderly patients receiving thymalin.
Mechanism of action
Thymalin restores thymic function by modulating T-cell differentiation and maturation. It normalizes the ratio of CD4/CD8 T-cells, enhances natural killer (NK) cell activity, stimulates phagocytosis, and modulates cytokine production. In aging, the thymus involutes (shrinks) dramatically, reducing naive T-cell output — thymalin appears to partially reverse this immunosenescence. It also regulates the neuroendocrine-immune axis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| immune restoration / anti-aging | intramuscular | 5–10 mg | daily | Standard Russian protocol: 5-10mg daily for 5-10 days. Repeat courses every 3-6 months. Often combined with Epithalon. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Khavinson's landmark study followed elderly patients for 6-15 years after treatment with thymalin + epithalon. The treatment group showed 1.6-1.8x lower mortality than controls. Thymalin normalized immunological markers, improved cardiovascular function, and reduced cancer incidence. Studies in post-surgical patients showed faster immune recovery and reduced infection rates. Approved in Russia for over 40 years with extensive clinical use. Limitations: most research is in Russian journals with limited Western replication.[1][2][3]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Thymalin for synergistic effects.
Legal status
Approved in Russia as a pharmaceutical since 1982. Not FDA-approved. Available as a research peptide internationally. Part of Khavinson's peptide bioregulator system.
Sourcing & access
Research compound
Thymalin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Thymalin is a peptide bioregulator derived from bovine thymus extracts, developed by Vladimir Khavinson. It has been approved and used in Russia since 1982 for immune restoration in immunocompromised patients, the elderly, and post-surgical recovery.
Thymalin restores thymic function by modulating T-cell differentiation and maturation. It normalizes CD4/CD8 T-cell ratios, enhances natural killer cell activity, stimulates phagocytosis, and modulates cytokine production, partially reversing age-related immunosenescence.
Thymalin has over 40 years of clinical use in Russia. Side effects include injection site reactions, mild allergic reactions (rare), and low-grade fever from immune activation. It is not FDA-approved and is available internationally as a research peptide.
Khavinson's landmark study followed elderly patients for 6-15 years. The thymalin plus epithalon treatment group showed 1.6-1.8x lower mortality than controls, with normalized immunological markers and reduced cancer incidence. Most research is in Russian journals with limited Western replication.